Inoviq Ltd - Asset Resilience Ratio
Inoviq Ltd (IIQ) has an Asset Resilience Ratio of 56.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Inoviq Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2025)
This chart shows how Inoviq Ltd's Asset Resilience Ratio has changed over time. See IIQ net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Inoviq Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Inoviq Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$13.80 Million | 56.29% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$13.80 Million | 56.29% |
Asset Resilience Insights
- Very High Liquidity: Inoviq Ltd maintains exceptional liquid asset reserves at 56.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Inoviq Ltd Industry Peers by Asset Resilience Ratio
Compare Inoviq Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.19% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 0.75% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Inoviq Ltd (1993–2025)
The table below shows the annual Asset Resilience Ratio data for Inoviq Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 35.33% | AU$6.52 Million ≈ $4.61 Million |
AU$18.46 Million ≈ $13.06 Million |
-7.21pp |
| 2024-06-30 | 42.54% | AU$9.23 Million ≈ $6.53 Million |
AU$21.71 Million ≈ $15.36 Million |
+6.22pp |
| 2023-06-30 | 36.32% | AU$7.81 Million ≈ $5.53 Million |
AU$21.51 Million ≈ $15.22 Million |
-13.69pp |
| 2022-06-30 | 50.02% | AU$15.39 Million ≈ $10.89 Million |
AU$30.78 Million ≈ $21.78 Million |
+35.11pp |
| 2021-06-30 | 14.91% | AU$5.00 Million ≈ $3.54 Million |
AU$33.52 Million ≈ $23.72 Million |
-84.45pp |
| 2020-06-30 | 99.36% | AU$7.33 Million ≈ $5.18 Million |
AU$7.37 Million ≈ $5.22 Million |
+0.27pp |
| 2019-06-30 | 99.08% | AU$7.56 Million ≈ $5.35 Million |
AU$7.63 Million ≈ $5.40 Million |
-0.40pp |
| 2018-06-30 | 99.49% | AU$1.45 Million ≈ $1.02 Million |
AU$1.45 Million ≈ $1.03 Million |
+98.71pp |
| 2016-06-30 | 0.78% | AU$25.65K ≈ $18.15K |
AU$3.29 Million ≈ $2.33 Million |
+0.58pp |
| 2015-06-30 | 0.20% | AU$3.62K ≈ $2.56K |
AU$1.85 Million ≈ $1.31 Million |
+0.06pp |
| 2014-06-30 | 0.14% | AU$3.89K ≈ $2.75K |
AU$2.82 Million ≈ $2.00 Million |
-2.98pp |
| 2013-06-30 | 3.12% | AU$131.65K ≈ $93.15K |
AU$4.23 Million ≈ $2.99 Million |
+2.06pp |
| 2012-06-30 | 1.06% | AU$172.15K ≈ $121.80K |
AU$16.29 Million ≈ $11.53 Million |
-1.97pp |
| 2011-06-30 | 3.02% | AU$811.50K ≈ $574.19K |
AU$26.85 Million ≈ $19.00 Million |
+1.19pp |
| 2010-06-30 | 1.83% | AU$358.99K ≈ $254.01K |
AU$19.60 Million ≈ $13.87 Million |
-0.56pp |
| 2009-06-30 | 2.39% | AU$477.55K ≈ $337.90K |
AU$19.96 Million ≈ $14.13 Million |
-9.46pp |
| 2008-06-30 | 11.86% | AU$727.10K ≈ $514.47K |
AU$6.13 Million ≈ $4.34 Million |
+11.84pp |
| 2005-06-30 | 0.02% | AU$2.63K ≈ $1.86K |
AU$17.44 Million ≈ $12.34 Million |
-0.16pp |
| 2004-06-30 | 0.17% | AU$6.10K ≈ $4.32K |
AU$3.50 Million ≈ $2.48 Million |
-4.28pp |
| 2003-06-30 | 4.46% | AU$118.68K ≈ $83.98K |
AU$2.66 Million ≈ $1.88 Million |
-17.54pp |
| 2002-06-30 | 22.00% | AU$631.88K ≈ $447.09K |
AU$2.87 Million ≈ $2.03 Million |
+21.77pp |
| 1999-06-30 | 0.23% | AU$21.66K ≈ $15.33K |
AU$9.47 Million ≈ $6.70 Million |
+0.14pp |
| 1998-06-30 | 0.08% | AU$9.80K ≈ $6.93K |
AU$11.57 Million ≈ $8.18 Million |
-1.27pp |
| 1997-06-30 | 1.36% | AU$153.49K ≈ $108.60K |
AU$11.33 Million ≈ $8.01 Million |
-4.67pp |
| 1996-06-30 | 6.02% | AU$688.76K ≈ $487.34K |
AU$11.44 Million ≈ $8.09 Million |
+0.40pp |
| 1995-06-30 | 5.62% | AU$591.00K ≈ $418.17K |
AU$10.51 Million ≈ $7.44 Million |
-0.48pp |
| 1994-06-30 | 6.10% | AU$641.00K ≈ $453.55K |
AU$10.50 Million ≈ $7.43 Million |
-8.68pp |
| 1993-06-30 | 14.79% | AU$346.00K ≈ $244.82K |
AU$2.34 Million ≈ $1.66 Million |
-- |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more